LETTERS TO THE EDITOR

LETTERS/COLUMNS: SEND LETTERS TO THE EDITOR FOR PUBLISHING TO FRONTPAGENEWS1@YAHOO.COM. PLEASE INCLUDE DAY/EVENING/ CELL NUMBER, HOME NUMBER, AND EMAIL. CONTACT VAN STONE: FRONTPAGENEWS1@YAHOO.COM OR (215) 821-9147 TO SUBMIT A REQUEST FOR ANY WRITER. PLEASE DO NOT CONTACT THE WRITER DIRECTLY! ALL APPEARANCE REQUEST WILL GO THROUGH THE MANAGING EDITOR'S OFFICE. COPYRIGHT: THE USE OF ANY SUBMISSIONS APPEARING ON THIS SITE FOR MONETARY GAINS IS STRICTLY PROHIBITED. TO LEARN MORE: PHILADELPHIA FRONT PAGE NEWS WWW.FPNNEWS.ORG. YOUR TOP STORIES OF THE DAY (215) 821-9147.

Tuesday, August 18, 2015

FDA approves female sex pill, but with safety restrictions

FDA approves female sex pill, but with safety restrictions 
 

AP Photo
FILE - In this June 22, 2015, photo, a tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters. The Food and Drug Administration on Tuesday, Aug. 18, 2015, approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.
  
WASHINGTON (AP) -- The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.

But stringent safety measures on the daily pill called Addyi mean it will probably never achieve the sales of Viagra, which has generated billions of dollars since the late 1990s.

The drug's label will bear a boxed warning - the most serious type - alerting doctors and patients to the risks of dangerously low blood pressure and fainting, especially when the pill is combined with alcohol. The same problems can occur when taking the drug with other commonly prescribed medications, including antifungals used to treat yeast infections.

"Patients and prescribers should fully understand the risks associated with the use of Addyi before considering treatment," said Dr. Janet Woodcock, director of the FDA's drug center, in a statement.

Under an FDA-imposed safety plan, doctors will only be able to prescribe Addyi after completing an online certification process that requires counseling patients about Addyi's risks. Pharmacists will also need certification and will be required to remind patients not to drink alcohol while taking the drug.

Opponents of the drug say it's not worth the side effects, which also include nausea, drowsiness and dizziness. They point out that the FDA rejected the drug twice, in 2010 and 2013, due to these risks.

"This is not a drug you take an hour before you have sex. You have to take it for weeks and months in order to see any benefit at all," said Leonore Tiefer, a psychologist and sex therapist who organized a petition last month calling on the FDA to reject the drug.

Patients should stop taking the drug after eight weeks if they do not see any improvement, notes the FDA release.

Sprout Pharmaceutical's drug is intended to treat women who report emotional stress due to a lack of libido. Its approval marks a turnaround for the FDA, which previously rejected the drug twice due to lackluster effectiveness and side effects. The decision represents a compromise of sorts between two camps that have publicly feuded over the drug for years.

On one side, Sprout and its supporters have argued that women desperately need FDA-approved medicines to treat sexual problems. On the other side, safety advocates and pharmaceutical critics warn that Addyi is a problem-prone drug for a questionable medical condition.

Beginning with the drug's launch in mid-October, doctors who see patients complaining about a loss of sexual appetite will have a new option.

"Women are grasping, and I feel like we need to offer them something that acknowledges that, and that we can feel safe and comfortable with," said Dr. Cheryl Iglesia, a surgeon and official with the American Congress of Obstetricians and Gynecologists. Iglesia said she has occasionally resorted to prescribing testosterone creams to boost women's libido, a use not approved by the FDA.

The search for a pill to treat women's sexual difficulties has been something of a holy grail for the pharmaceutical industry. It was pursued and later abandoned by Pfizer, Bayer and Procter & Gamble, among others. But drugs that act on blood flow, hormones and other biological functions all proved ineffective.

Addyi, known generically as flibanserin, is the first drug that acts on brain chemicals that affect mood and appetite.

Women and their doctors will have to decide whether the drug's modest benefits warrant taking a psychiatric pill on a daily basis.

Company trials showed women taking the drug generally reported one extra "sexually satisfying event" per month, and scored higher on questionnaires measuring desire.

Tiefer and other critics said the FDA was pressured into approving the drug by a feminist-themed lobbying campaign funded by Sprout and other drugmakers.

"It's just a mishmash of politics and science and sex and money," Tiefer said.

The lobbying group, dubbed Even the Score, began publicizing the lack of drugs for female sexual dysfunction as a women's rights issue last year.

"Women deserve equal treatment when it comes to sex," the group states in an online petition to the FDA, which attracted more than 60,000 supporters. Women's groups, including the National Organization for Women, signed on to the effort, though it was funded by Sprout and other companies working on female sex drugs.

At an FDA meeting in June, more than 30 members of the public called for the drug's approval, frequently citing the Even the Score campaign. They vastly outnumbered speakers who spoke in opposition to the drug. At the meeting's conclusion, the panel of FDA advisers voted 18-6 to recommend approving the drug, with safety restrictions.

Sprout declined to comment on how much it spent on the campaign.

For now, executives with the Raleigh, North Carolina-based company are setting modest expectations for Addyi, their first and only product. The company will focus its 200 sales representatives on promoting the drug to medical specialists.

"We will be small," CEO Cindy Whitehead said. "We will be specialty focused among the physicians who already have a familiarity with female sexual dysfunction."

Women with insurance can expect to pay between $30 and $75 per month for Addyi, depending on the terms of their coverage.

The FDA specifically approved the drug for premenopausal women with hypoactive sexual desire disorder, a lack of sexual appetite that causes distress.

Surveys estimate that 8 to 14 percent of women ages 20 to 49 have the condition, or about 5.5 to 8.6 million U.S. women. Because so many factors affect sexual appetite, there are a number of alternate causes doctors must rule out before diagnosing the condition, including relationship issues, medical problems, depression and mood disorders.

The diagnosis is not universally accepted, and some psychologists argue that low sex drive should not be considered a medical problem.

Van Stone Productions Inc. 501C3 Nonprofit Organization Informatioin (EIN) / Tax ID

Van Stone Productions Inc. 501C3 Nonprofit Organization Informatioin (EIN) / Tax ID
Click on the logo to learn about the non-profit status

BECOME OUR VLOGGER OF THE MONTH: VIDEO NEWS CONTENT PUBLISHED ON ANY TOPIC BELOW

Latest edition of Talk Live Philly With Van Stone

VAN STONE PERFORMANCE PROMOTION VIDEO AT WEST PHILADELPHIA HS 1999 - BELOW

FPN NEWS “TAKE TIME FOR WINNERS IN ANY COMMUNITY!”

Van Stones' Beautiful World Images -Latinamerica, South Asia, and USA Fashion and Beauty Collection

Van Stones' Beautiful World Images -Latinamerica, South Asia, and USA Fashion and Beauty Collection
Family Modeling -modelado de la familia

Van Stones' Beautiful World Images -Hermosas World Images Van Stones

Van Stones' Beautiful World Images -Hermosas World Images Van Stones
Family Modeling -modelado de la familia

WE'RE #1

WE'RE #1

Van Stones' Beautiful World Images -Hermosas World Images Van Stones

Van Stones' Beautiful World Images -Hermosas World Images Van Stones
Family Modeling -modelado de la familia

Van Stones' Beautiful Tween Images-Hermosas Imágenes Tween Van Stones

Van Stones' Beautiful Tween Images-Hermosas Imágenes Tween Van Stones
Family Modeling -modelado de la familia

WE'RE NO 1

WE'RE NO 1

Van Stones' Beautiful Youth Images -Van Stones imágenes hermosas de la Juventud

Van Stones' Beautiful Youth Images -Van Stones imágenes hermosas de la Juventud
Family Modeling -Modelado de la familia

WE'RE NO 1

WE'RE NO 1

Van Stones' Beautiful Child Images -Van Stones Niño hermoso Imágenes

WE'RE #1

Van Stones’ Beautiful Children Images - Van Stones imágenes hermosas Madre

Van Stones’ Beautiful Children Images - Van Stones imágenes hermosas Madre
Family Modeling -modelado de la familia

Like Us On Facebook

We"re Looking For Volunteers

News, and more about youth, education, political analyst, schools, anti-violence, social justice, grass roots democracy, ecological protection, seniors, Historic Preservation & Restoration, (Black, Latinos, Asian, Pakistani, Italian, and other)Arts, Books, Super Heroes, Trading Cards, Youth, College, and Pro Sports, Nonprofits and Real-estate.

Blog Archive

About Us

  • FPN can reach out to Representatives from your side of: The Village, The Township, or The City
  • FPN features
    Sports
    Cars
    Family Entertainment
    Neighborhood News
    Scholastic News
    Regional News
    National News
    Citywide News
    Legal News
    Alternative Green Energy Education News
    Superhero & Comic Strip News
  • Teen Stars
  • Humanitarian/Ministers/Political
  • Community Services
  • Women & Men & Kids

  • You acknowledge and agree that you may not copy, distribute, sell, resell or exploit for any commercial purposes, any portion of the Newspaper or Services. Unless otherwise expressly provided in our Newspaper, you may not copy, display or use any trademark without prior written permission of the trademark owner.

    FPN/VSP® is in no way responsible for the content of any site owned by a third party that may be listed on our Website and/or linked to our Website via hyperlink. VSP/FPN® makes no judgment or warranty with respect to the accuracy, timeliness or suitability of the content of any site to which the Website may refer and/or link, and FPN/VSP® takes no responsibility therefor. By providing access to other websites, FPN/VSP® is not endorsing the goods or services provided by any such websites or their sponsoring organizations, nor does such reference or link mean that any third party websites or their owners are endorsing FPN/VSP® or any of the Services. Such references and links are for informational purposes only and as a convenience to you.

    FPN/VSP® reserves the right at any time to modify or discontinue, temporarily or permanently, the Website and/or Services (or any part thereof) with or without notice to you. You agree that neither FPN/VSP® nor its affiliates shall be liable to you or to any third party for any modification, suspension or discontinuance of the Website and/or Services.

    You agree to indemnify and hold harmless FPN/VSP®, its subsidiaries, and affiliates, and their respective officers, directors, employees, shareholders, legal representatives, agents, successors and assigns, from and against any and all claims, actions, demands, causes of action and other proceedings arising from or concerning your use of the Services (collectively, "Claims") and to reimburse them on demand for any losses, costs, judgments, fees, fines and other expenses they incur (including attorneys' fees and litigation costs) as a result of any Claims.

    The Website is © 2009 by VSP®, or its designers. All rights reserved. Your rights with respect to use of the Website and Services are governed by the Terms and all applicable laws, including but not limited to intellectual property laws.

    Any contact information for troops overseas and/or soldiers at home provided to you by FPN/VSP® is specifically and solely for your individual use in connection with the services provide by Van Stone Productions Foundation VSP.

    FPN/VSP® soldiers contact information for any other purpose whatsoever, including, but not limited to, copying and/or storing by any means (manually, electronically, mechanically, or otherwise) not expressly authorized by FPN/VSP is strictly prohibited. Additionally, use of FPN/VSP® contact information for any solicitation or recruiting purpose, or any other private, commercial, political, or religious mailing, or any other form of communication not expressly authorized by FPN/VSP® is strictly prohibited.